Strides Pharma receives USFDA approval for Prednisone tablets

▴ Strides Pharma receives USFDA approval for Prednisone tablets
Strides Pharma gets USFDA approval for their anti-inflammatory drug Prednisone (tablets)

Drug firm Strides Pharma Science reported,  approval from the US health regulator for generic Prednisone tablets used as an anti-inflammatory medication. Strides Pharma  has received approval for Prednisone tablets USP in the strength of 1 mg from the United States Food & Drug Administration (USFDA), Strides Pharma Science said in a filing to the BSE.

The product is a generic version of Schering Corporation's Meticorten tablets in the same strength, it added. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market,the filing said.

According to IQVIA MAT July 2020 data, the US market for Prednisone tablets USP 1 mg is approximately USD 12 million (about Rs 88 crore), it added. Prednisone belongs to a class of drugs known as corticosteroids and is used as an anti-inflammatory or an immunosuppressant medication.

It is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders, Strides said. The company has 126 cumulative abbreviated new drug application (ANDA) filings with USFDA of which 89 ANDAs have been approved and 37 are pending approval,it added.

Recently, the company also USFDA approval for Ursodiol tablets USP in the strengths of 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) for treatment of PBC.

PBC is a progressive disease of the liver caused by a buildup of bile within the liver that results in damage to the small bile ducts that drain bile from the liver.

"Strides Pharma Global, Singapore, has received approval for ," the company said in a regulatory filing.

The product is a generic version of Urso 250 tablets, 250 mg, and Urso Forte Tablets, 500 mg, of Allergan Sales, LLC.

Quoting IQVIA moving annual total (MAT) June 2020 data, Strides Pharma Science said the US market for Ursodiol tablets USP, 250 mg and 500 mg, is approximately $35 million.

According to the company , the product will be manufactured at the company''s flagship facility at Bengaluru and will be marketed by Strides Pharma in the US markets.

Tags : #StridesPharmaUSFDAApproval #PrednisoneTablets #IQVIAMat #PBCofLiver #LatestPharmaApprovalNewsUpdateSep4 #LatestPharmaNewsUpdateSep4 #StridesPharmaNewsUpdate

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
Top 5 online learning platform for learnersApril 17, 2024
Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024
CarDekho's CSR Arm Girnar Foundation Hosts Health Check-up Camps for Underprivileged Children in Jaipur and GurugramApril 16, 2024
Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 16, 2024
AVEKSHA, four-day care centres, for the kids of industrial workers inauguratedApril 16, 2024
Nearly a third of the constituencies have zero women candidates in Phase 1 and 2 of LS Elections; reveals The Quantum Hub’s Factsheet April 16, 2024
Emergency Healthcare Provider Medulance Secures $3 Million Series A Funding Led by Alkemi Growth CapitalApril 16, 2024
The Healing Power of Natural Diversity: How Nature Boosts Mental HealthApril 16, 2024
Unveiling Cellular Recycling: How Nutrient-Starved Cells Adapt to Stressful ConditionsApril 16, 2024
Advancing Cancer Care: AIIMS Bhopal’s Workshop on Biomarker Interpretation in Breast CancerApril 15, 2024
10 Powerful Benefits to Diversify Healthcare Advertising ChannelsApril 15, 2024
Understanding Hospital Sink Contamination: Challenges in Fighting Multidrug-Resistant BacteriaApril 15, 2024
Rajasthan’s Swine Flu Situation: Health Department Observes DeclineApril 15, 2024
Is Your Doctor’s Prescription Incomplete ? Insights from Recent ICMR Study Suggests So!April 13, 2024